Lantern Pharma announces $7M share repurchase program

Lantern Pharma Inc.

Board authorized up to $7M of common stock repurchases.
Cash and equivalents totaled $73.8M as of Sept 30, 2021.
Approximately 11.2M shares outstanding as of Oct 29, 2021.
CEO states program reflects confidence in pipeline and platform.
Repurchases may occur on open market or privately; program can be modified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.